🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to health experts.

An International Health Concern

Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million infections per year. Notably increased rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was approved by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in close succession. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the drug firm Innoviva to see it through.

“This authorization represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Research Study Outcomes and Global Access

According to findings released by a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial enrolled hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the ability to register and commercialise the drug in numerous developing nations.

Medical professionals treating patients have voiced hope. The availability of a one-pill regimen like this is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to reduce the burden of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea globally.